Product
Recombinant new coronavirus vaccine
Aliases
Recombinant new coronavirus vaccine (CHO cell)
4 clinical trials
1 indication
Indication
COVID-19Clinical trial
Multi-center Safety Observation of COVID19 Vaccine in a Large PopulationStatus: Recruiting, Estimated PCD: 2022-06-16
Clinical trial
A Randomized, Blinded, Placebo-controlled Phase Ⅰ Clinical Trial of Recombinant New Coronavirus Vaccine (CHO Cells) in the Safety and Tolerability of Healthy People Aged 3 to 17 Years of AgeStatus: Completed, Estimated PCD: 2021-12-12
Clinical trial
A Clinical Trial Comparing the Immunogenicity of Recombinant New Coronavirus Vaccine (CHO Cells) Among People Aged 3 to 17 and 18 to 59 Years of Age.Status: Completed, Estimated PCD: 2022-02-14
Clinical trial
Clinical Study on Immunogenicity and Safety of Recombinant Novel Coronavirus（COVID-19）Vaccine (CHO Cell) Combined With Tetravalent Influenza Virus Lysis Vaccine in People Aged 18 Years and OverStatus: Completed, Estimated PCD: 2022-03-04